Report Detail

Nuclear Medicine/Radiopharmaceuticals Market to 2027 - Global Analysis and Forecasts by Applications (Diagnostic Applications, Therapeutic Applications); End User (Hospitals, Diagnostic Centers) and Geography

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Nuclear Medicine/Radiopharmaceuticals Market – By Applications
    • 1.3.2 Global Nuclear Medicine/Radiopharmaceuticals Market – By End User
    • 1.3.3 Global Nuclear Medicine/Radiopharmaceuticals Market – By Geography

2. Global Nuclear Medicine/Radiopharmaceuticals Market – Key Takeaways

    3. Research Methodology

    • 3.1 Coverage
    • 3.2 Secondary Research
    • 3.3 Primary Research

    4. Global Nuclear Medicine/Radiopharmaceuticals Market – Market Landscape

    • 4.1 Overview
    • 4.2 PEST Analysis
      • 4.2.1 North America PEST Analysis
      • 4.2.2 Europe PEST Analysis
      • 4.2.3 Asia Pacific PEST Analysis
      • 4.2.4 Middle East & Africa PEST Analysis
      • 4.2.5 South & Central America PEST Analysis

    5. Global Nuclear Medicine/Radiopharmaceuticals market – Key Industry Dynamics

    • 5.1 Key Market Drivers
      • 5.1.1 Rising Prevalence of Chronic Diseases
      • 5.1.2 Alpha Radioimmunotherapy-Based Targeted Oncology Treatment
      • 5.1.3 Advancement in Imaging Technologies using Radiopharmaceuticals
    • 5.2 Key Market Restraints
      • 5.2.1 Short Shelf-Life of Radiopharmaceuticals
      • 5.2.2 Availability of Substitutes of Radiopharmaceuticals
    • 5.3 Key Market Opportunities
      • 5.3.1 Development in the Healthcare Market
      • 5.3.2 High Market Potential in Emerging Nations
    • 5.4 Current Trend
      • 5.4.1 Use of Nuclear Medicine For Personalized Treatment
    • 5.5 Impact Analysis

    6. Nuclear Medicine/Radiopharmaceuticals Market – Global Analysis

    • 6.1 Global Nuclear Medicine/Radiopharmaceuticals Market Revenue Forecasts and Analysis
    • 6.2 Global Nuclear Medicine/Radiopharmaceuticals Market, By Geography - Forecasts and Analysis
    • 6.3 Performance/ Positioning of Key Players
      • 6.3.1 Cardinal Health
      • 6.3.2 GENERAL ELECTRIC

    7. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis– by Applications

    • 7.1 Overview
    • 7.2 Global Nuclear Medicine/Radiopharmaceuticals Market BY applications, 2018 & 2027 (%)
    • 7.3 Diagnostic Applications Market
      • 7.3.1 Overview
      • 7.3.2 Global Diagnostic Applications Market Revenue and Forecasts to 2027 (US$ Mn)
      • 7.3.3 SPECT (Single-Photon Emission Computed Tomography) Applications Market
        • 7.3.3.1 Overview
        • 7.3.3.2 Global SPECT (Single-Photon Emission Computed Tomography) Applications Market Revenue and Forecasts to 2027 (US$ Mn)
      • 7.3.4 PET (Positron Emission Tomography) Applications Market
        • 7.3.4.1 Overview
        • 7.3.4.2 Global PET (Positron Emission Tomography) Applications Market Revenue and Forecasts to 2027 (US$ Mn)
      • 7.4 Therapeutic Applications Market
        • 7.4.1 Overview
        • 7.4.2 Global Therapeutic Applications Market Revenue and Forecasts to 2027 (US$ Mn)
        • 7.4.3 Thyroid Market
          • 7.4.3.1 Overview
          • 7.4.3.2 Global Thyroid Market Revenue and Forecasts to 2027 (US$ Mn)
        • 7.4.4 Bone Metastasis Market
          • 7.4.4.1 Overview
          • 7.4.4.2 Global Bone Metastasis Market Revenue and Forecasts to 2027 (US$ Mn)
        • 7.4.5 Lymphoma Market
          • 7.4.5.1 Overview
          • 7.4.5.2 Global Lymphoma Market Revenue and Forecasts to 2027 (US$ Mn)
        • 7.4.6 Endocrine Tumors Market
          • 7.4.6.1 Overview
          • 7.4.6.2 Global Endocrine Tumors Market Revenue and Forecasts to 2027 (US$ Mn)
        • 7.4.7 Other Therapeutic Applications Market
          • 7.4.7.1 Overview
          • 7.4.7.2 Global Other Therapeutic Applications Market Revenue and Forecasts to 2027 (US$ Mn)

        8. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis– by End User

        • 8.1 Overview
        • 8.2 Global Nuclear Medicine/Radiopharmaceuticals Market, BY ENd User 2018 & 2027 (%)
        • 8.3 Hospitals market
          • 8.3.1 Overview
          • 8.3.2 Global Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
        • 8.4 Diagnostic Centers Market
          • 8.4.1 Overview
          • 8.4.2 Global Diagnostic Centers Market Revenue and Forecasts to 2025 (US$ Mn)

        9. Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 – Geographical Analysis

        • 9.1 North America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
          • 9.1.1 North America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.2 North America Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.1.2.1 North America Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.1.2.2 North America Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
          • 9.1.3 North America Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.1.4 North America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027, By Country (%)
          • 9.1.5 US Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.1.6 US Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.1.6.1 US Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.1.6.1.1 US Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.1.6.1.2 US Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.1.6.2 US Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.1.7 Canada Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.1.7.1 Canada Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.1.7.2 Canada Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.1.7.2.1 Canada Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.1.7.2.2 Canada Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.1.7.3 Canada Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
            • 9.1.7.4 Mexico Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.1.7.5 Mexico Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.1.7.6 Mexico Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.1.7.6.1 Mexico Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.1.7.6.2 Mexico Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.1.7.7 Mexico Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.2 Europe Nuclear Medicine/Radiopharmaceuticals market Revenue and Forecasts to 2027
          • 9.2.1 Europe Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.2.2 Europe Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.2.2.1 Europe Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.2.2 Europe Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
          • 9.2.3 Europe Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.2.4 Europe Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Country (%)
          • 9.2.5 UK Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.5.1 UK Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.5.2 UK Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.2.5.2.1 UK Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.5.2.2 UK Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.5.3 UK Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.2.6 Germany Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.6.1 Germany Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.6.2 Germany Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.2.6.2.1 Germany Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.6.2.2 Germany Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.6.3 Germany Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.2.7 France Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.7.1 France Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.7.2 France Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.2.7.2.1 France Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.7.2.2 France Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.7.3 France Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.2.8 Italy Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.8.1 Italy Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.8.2 Italy Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.2.8.2.1 Italy Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.8.2.2 Italy Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.8.3 Italy Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.2.9 Spain Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.9.1 Spain Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.2.9.2 Spain Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.2.9.2.1 Spain Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.9.2.2 Spain Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.2.9.3 Spain Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.3 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
          • 9.3.1 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.3.2 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.3.2.1 Asia Pacific Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.2.2 Asia Pacific Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
          • 9.3.3 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.3.4 Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027, By Country (%)
          • 9.3.5 Japan Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.5.1 Japan Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.5.2 Japan Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.3.5.2.1 Japan Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.5.2.2 Japan Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.5.3 Japan Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.3.6 China Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.6.1 China Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.6.2 China Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.3.6.2.1 China Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.6.2.2 China Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.6.3 China Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.3.7 India Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.7.1 India Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.7.2 India Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.3.7.2.1 India Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.7.2.2 India Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.7.3 India Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
            • 9.3.7.4 South Korea Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.7.5 South Korea Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.7.6 South Korea Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.3.7.6.1 South Korea Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.7.6.2 South Korea Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.7.7 South Korea Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.3.8 Australia Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.8.1 Australia Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.3.8.2 Australia Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.3.8.2.1 Australia Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.8.2.2 Australia Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.3.8.3 Australia Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.4 Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
          • 9.4.1 Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.4.2 Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.4.2.1 Middle East & Africa Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.4.2.2 Middle East & Africa Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
        • 9.5 Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.5.1 Middle East & Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027, By Country (%)
          • 9.5.2 UAE Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.5.2.1 UAE Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.5.2.2 UAE Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.5.2.2.1 UAE Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.5.2.2.2 UAE Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.5.2.3 UAE Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.5.3 Saudi Arabia Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.5.3.1 Saudi Arabia Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.5.3.2 Saudi Arabia Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.5.3.2.1 Saudi Arabia Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.5.3.2.2 Saudi Arabia Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.5.3.3 Saudi Arabia Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.5.4 South Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.5.4.1 South Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.5.4.2 South Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.5.4.2.1 South Africa Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.5.4.2.2 South Africa Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.5.4.3 South Africa Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
        • 9.6 South and Central America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027
          • 9.6.1 South and Central America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
          • 9.6.2 South and Central America Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.6.2.1 South and Central America Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.6.2.2 South and Central America Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
          • 9.6.3 South and Central America Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.6.4 South and Central America Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027, By Country (%)
          • 9.6.5 Argentina Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.6.5.1 Argentina Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.6.5.2 Argentina Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.6.5.2.1 Argentina Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.6.5.2.2 Argentina Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.6.5.3 Argentina Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)
          • 9.6.6 Brazil Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.6.6.1 Brazil Nuclear Medicine/Radiopharmaceuticals Market Revenue and Forecasts to 2027 (US$ Mn)
            • 9.6.6.2 Brazil Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By Applications (US$ Mn)
            • 9.6.6.2.1 Brazil Diagnostic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.6.6.2.2 Brazil Therapeutic Applications Market Revenue And Forecasts to 2027, By Type (US$ Mn)
            • 9.6.6.3 Brazil Nuclear Medicine/Radiopharmaceuticals Market Revenue And Forecasts to 2027, By End User (US$ Mn)

          10. Nuclear Medicine/Radiopharmaceuticals Market– Industry Landscape

          • 10.1 Overview
          • 10.2 Comparative Company Analysis
          • 10.3 Growth Strategies done by the companies in the Market, (%)
          • 10.4 Organic Developments
            • 10.4.1 Overview
          • 10.5 Inorganic developments
            • 10.5.1 Overview

          11. Nuclear Medicine/Radiopharmaceuticals Market–Key Company Profiles

          • 11.1 Cardinal Health
            • 11.1.1 Key Facts
            • 11.1.2 Business Description
            • 11.1.3 Financial Information
            • 11.1.4 Product Portfolio
            • 11.1.5 Swot Analysis
            • 11.1.6 Key Developments
          • 11.2 GENERAL ELECTRIC
            • 11.2.1 Key Facts
            • 11.2.2 Business Description
            • 11.2.3 Financial Overview
            • 11.2.4 Product Portfolio
            • 11.2.5 SWOT Analysis
            • 11.2.6 Key Developments
          • 11.3 IBA Worldwide
            • 11.3.1 Key Facts
            • 11.3.2 Business Description
            • 11.3.3 Financial Overview
            • 11.3.4 Product Portfolio
            • 11.3.5 SWOT Analysis
            • 11.3.6 Key Developments
          • 11.4 Curium
            • 11.4.1 Key Facts
            • 11.4.2 Business Description
            • 11.4.1 Financial Information
            • 11.4.2 Product Portfolio
            • 11.4.3 SWOT Analysis
            • 11.4.4 Key Developments
          • 11.5 Positron Corporation
            • 11.5.1 Key Facts
            • 11.5.2 Business Description
            • 11.5.3 Financial Overview
            • 11.5.4 Product Portfolio
            • 11.5.5 SWOT Analysis
            • 11.5.6 Key Developments
          • 11.6 Lantheus Medical Imaging, Inc.
            • 11.6.1 Key Facts
            • 11.6.2 Business Description
            • 11.6.3 Financial Information
            • 11.6.4 Product Portfolio
            • 11.6.5 Product Pipeline
            • 11.6.6 SWOT Analysis
            • 11.6.7 Key Developments
          • 11.7 NTP Radioisotopes SOC Ltd (Necsa)
            • 11.7.1 Key Facts
            • 11.7.2 Business Description
            • 11.7.3 Financial Overview
            • 11.7.4 Product Portfolio
            • 11.7.5 SWOT Analysis
            • 11.7.6 Key Developments
          • 11.8 BAYER AG
            • 11.8.1 Key Facts
            • 11.8.2 Business Description
            • 11.8.3 Financial Overview
            • 11.8.4 Product Portfolio
            • 11.8.5 Product Pipeline
            • 11.8.6 SWOT Analysis
            • 11.8.7 Key Developments
          • 11.9 Bracco
            • 11.9.1 Key Facts
            • 11.9.2 Business Description
            • 11.9.3 Financial Overview
            • 11.9.4 Product Portfolio
            • 11.9.5 SWOT Analysis
            • 11.9.6 Key Developments
          • 11.10 Advanced Accelerator Applications (Novartis AG)
            • 11.10.1 Key Facts
            • 11.10.2 Business Description
            • 11.10.3 Financial Overview
            • 11.10.4 Product Portfolio
            • 11.10.5 Product Pipeline
            • 11.10.6 SWOT Analysis
            • 11.10.7 Key Developments

          12. Appendix

          • 12.1 About The Insight Partners

    The global nuclear medicine/radiopharmaceuticals market is expected to reach US$ 6,683.99 Mn in 2027 from US$ 3,982.11 Mn in 2018. The market is estimated to grow with a CAGR of 6.2% from 2019-2027.
    The market for nuclear medicine/radiopharmaceuticals is expected to grow, owing to factors such as rising prevalence of chronic diseases, alpha radioimmunotherapy-based targeted oncology treatment and advancement in imaging technologies using radiopharmaceuticals play vital role in the growth of the radiopharmaceuticals market. However, the restraints such as short shelf-life of radiopharmaceuticals and availability of substitutes of radiopharmaceuticals are likely to impact the growth of the market in the forecast period.
    A radiopharmaceutical is a drug, which can be used either for diagnostic or therapeutic purposes. Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. These rays are detected by a specific device, which is usually single-photon emission computed tomography (SPECT)/ positron emission tomography (PET) cameras.
    The shelf-life or expiry date of a radiopharmaceutical preparation depends mainly on the half-life of the radioisotope, the radiochemical stability and the content of longer-lived radionuclide impurities in the preparation under consideration. Most of the radiopharmaceutical preparations contain radioisotopes with very short half-lives and such preparations have very short shelf-lives. These preparations require an expiry date and time to be indicated. For example, technetium based preparations and positron emission tomography (PET) preparations are generally intended to be used within less than 12 hours, or sometimes within few minutes of preparation. Hence, the short shelf-life of radiopharmaceuticals are expected to hinder the growth of the market in the future years.
    Global nuclear medicine/radiopharmaceuticals were segmented by application and end user. The application segment was segmented as diagnostic applications and therapeutic applications. Based on the end user, the market was segmented as hospitals and diagnostic centers. During 2018, the hospitals segment led the nuclear medicine/radiopharmaceuticals market by the end user.
    Some of the major primary and secondary sources included in the report for, Society of Nuclear Medicine, Food and Drug Administration, American Cancer Society, World Health Organization, American Hospital Association (AHA), National Cancer Institute (NCI), Canadian Association of Nuclear Medicine, and others.


    Summary:
    Get latest Market Research Reports on Nuclear Medicine/Radiopharmaceuticals . Industry analysis & Market Report on Nuclear Medicine/Radiopharmaceuticals is a syndicated market report, published as Nuclear Medicine/Radiopharmaceuticals Market to 2027 - Global Analysis and Forecasts by Applications (Diagnostic Applications, Therapeutic Applications); End User (Hospitals, Diagnostic Centers) and Geography. It is complete Research Study and Industry Analysis of Nuclear Medicine/Radiopharmaceuticals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $4,550.00
    $6,550.00
    $8,550.00
    3,658.20
    5,266.20
    6,874.20
    4,125.69
    5,939.19
    7,752.68
    491,891.40
    708,107.40
    924,323.40
    326,261.85
    469,673.65
    613,085.45
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report